Parkinson disease: Can a new trial end controversy over when to use levodopa?
Identifieur interne : 000895 ( Main/Exploration ); précédent : 000894; suivant : 000896Parkinson disease: Can a new trial end controversy over when to use levodopa?
Auteurs : Olivier Rascol [France]Source :
- Nature reviews. Neurology [ 1759-4766 ] ; 2014.
English descriptors
- KwdEn :
- MESH :
- chemical , therapeutic use : Antiparkinson Agents, Dopamine Agents, Levodopa.
- drug therapy : Parkinson Disease.
- Humans, Randomized Controlled Trials as Topic, Treatment Outcome.
Abstract
Levodopa is the standard therapy for Parkinson disease, but prolonged use promotes the development of adverse motor effects. A new trial compared the effectiveness of levodopa administration early in the disease with therapies that used alternative dopaminergic agents before levodopa. No clinically relevant differences were found between the treatment strategies.
DOI: 10.1038/nrneurol.2014.147
PubMed: 25134709
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000517
- to stream PubMed, to step Curation: 000502
- to stream PubMed, to step Checkpoint: 000502
- to stream Ncbi, to step Merge: 001482
- to stream Ncbi, to step Curation: 001482
- to stream Ncbi, to step Checkpoint: 001482
- to stream Main, to step Merge: 000902
- to stream Main, to step Curation: 000895
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Parkinson disease: Can a new trial end controversy over when to use levodopa?</title><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation wicri:level="3"><nlm:affiliation>Clinical Investigation Centre CIC1436, Departments of Clinical Pharmacology and Neurosciences, INSERM and Toulouse University Hospital, University of Toulouse 3, Place du Docteur Baylac, TSA 40031, 31059 Toulouse CEDEX 9, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Clinical Investigation Centre CIC1436, Departments of Clinical Pharmacology and Neurosciences, INSERM and Toulouse University Hospital, University of Toulouse 3, Place du Docteur Baylac, TSA 40031, 31059 Toulouse CEDEX 9</wicri:regionArea><placeName><region type="region" nuts="2">Occitanie (région administrative)</region><region type="old region" nuts="2">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:25134709</idno><idno type="pmid">25134709</idno><idno type="doi">10.1038/nrneurol.2014.147</idno><idno type="wicri:Area/PubMed/Corpus">000517</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000517</idno><idno type="wicri:Area/PubMed/Curation">000502</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000502</idno><idno type="wicri:Area/PubMed/Checkpoint">000502</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000502</idno><idno type="wicri:Area/Ncbi/Merge">001482</idno><idno type="wicri:Area/Ncbi/Curation">001482</idno><idno type="wicri:Area/Ncbi/Checkpoint">001482</idno><idno type="wicri:Area/Main/Merge">000902</idno><idno type="wicri:Area/Main/Curation">000895</idno><idno type="wicri:Area/Main/Exploration">000895</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Parkinson disease: Can a new trial end controversy over when to use levodopa?</title><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation wicri:level="3"><nlm:affiliation>Clinical Investigation Centre CIC1436, Departments of Clinical Pharmacology and Neurosciences, INSERM and Toulouse University Hospital, University of Toulouse 3, Place du Docteur Baylac, TSA 40031, 31059 Toulouse CEDEX 9, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Clinical Investigation Centre CIC1436, Departments of Clinical Pharmacology and Neurosciences, INSERM and Toulouse University Hospital, University of Toulouse 3, Place du Docteur Baylac, TSA 40031, 31059 Toulouse CEDEX 9</wicri:regionArea><placeName><region type="region" nuts="2">Occitanie (région administrative)</region><region type="old region" nuts="2">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author></analytic><series><title level="j">Nature reviews. Neurology</title><idno type="eISSN">1759-4766</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiparkinson Agents (therapeutic use)</term><term>Dopamine Agents (therapeutic use)</term><term>Humans</term><term>Levodopa (therapeutic use)</term><term>Parkinson Disease (drug therapy)</term><term>Randomized Controlled Trials as Topic</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Dopamine Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term><term>Randomized Controlled Trials as Topic</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Levodopa is the standard therapy for Parkinson disease, but prolonged use promotes the development of adverse motor effects. A new trial compared the effectiveness of levodopa administration early in the disease with therapies that used alternative dopaminergic agents before levodopa. No clinically relevant differences were found between the treatment strategies.</div></front></TEI><affiliations><list><country><li>France</li></country><region><li>Midi-Pyrénées</li><li>Occitanie (région administrative)</li></region><settlement><li>Toulouse</li></settlement></list><tree><country name="France"><region name="Occitanie (région administrative)"><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000895 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000895 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:25134709
|texte= Parkinson disease: Can a new trial end controversy over when to use levodopa?
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:25134709" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |